跳至主要内容
临床试验/EUCTR2009-014548-13-IT
EUCTR2009-014548-13-IT进行中(未招募)不适用

Evaluation of chemopreventive effect of a galenic preparation, comparable to a food integrator, composed by seleniomethionine, lycopene and polyphenols (green tea epigallocatechingallate and catechins) in patients with high risk of prostate carcinoma: a randomized phase II study - ND

AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO0 个研究点开始时间: 2009年8月7日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • Age >45 and <75
  • Patients with first prostate biopsy negative for prostate carcinoma, but with multifocal HGPIN (&#8805;2 positive samples for HGPIN) or ASAP
  • Signed informed consent
  • Patient compliance allowing an adequate follow-up
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Previous or current therapy with food integrators with supposed protecting effect
  • Previous or current therapy with inhibitor of 5 alfa reductase (finasteride, dutasteride)
  • Neoplastic disease requiring a chemotherapy, radiotherapy or immunotherapy treatment
  • Concomitant disease that would interfere with protocol or results

研究者

发起方
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO

相似试验

已完成
不适用
Investigation of anti-tumoral effect and safety of combination therapy LD-GP (low dose gemcitabine and paclitaxel) therapy and sorafenib in patients with cisplatin-resistant advanced urothelial cancer.Cisplatin-resistant urothelial cancer
JPRN-UMIN000010957agasaki University Hospital15
招募中
1 期
hR3 MAb in combination with chemo-embolization in hepatocellular carcinoma.Liver NeoplasmsCarcinoma, HepatocellularDigestive System NeoplasmsLiver DiseasesDigestive System DiseasesAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialHepatocellular carcinoma
RPCEC00000022Center of Molecular Immunology (CIM)15
招募中
1 期
hR3 monoclonal antibody combined with chemoembolization in mestatatic liver treatment.Primary malignant colon and breast lesion and metastatic liver lesions.Liver NeoplasmsDigestive System NeoplasmsLiver DiseasesDigestive System Diseases
RPCEC00000023Center of Molecular Immunology (CIM)15
招募中
Unknown
Prospective study on efficacy of prophylactic gallbladder stent for preventing acute cholecystitis induced after use of metallic stent placement for malignant biliary stricturesmalignant biliary strictures, bile duct cancer, pancreatic cancer, cholecystitis
JPRN-UMIN000050327Sendai City Medical Center100
已完成
2 期
An investigation of antitumor effectiveness using M-VAC/CaG prediction system in neoadjuvant chemotherapy for muscle invasive bladder cancer.Muscle-invasive bladder cancer
JPRN-UMIN000019902Department of Urology, Iwate Medical University35
Evaluation of chemopreventive effect of a galenic... | 临床试验